INTRODUCTION
Kinases are known to be a viable target for anti-cancer drug development [1] [2] [3] [4] . It's estimated that around 30% of all drug design effort are dedicated for inhibition of kinases [5] . They are the second most important drug targets after GPCR's (G Protein Coupled Receptors) [6] . Kinases are involved in many pathophysiological problems especially cancers where their over-expression can lead to certain types of malignant tumours [7, 8] . Several kinase inhibitors are now in the market and many are under clinical trials. Resistance to current kinase inhibitors are emerging and widespreading, so, there's an urgent need for the development of more effective analogues that can tackle the problem of resistance [9] . In our two previous studies, we have presented a new series of a quinazoline based Lapatinib analogues with a potential
anti-tumour activity and tested them against Epidermal Growth Factor Receptors and Human Epidermal growth factor Receptors 2 tyrosine kinases (EGFR/HER2) [10, 11] .
Indeed, several members of the new family showed micro-molar inhibitory activities and utilizing new binding patterns [10, 11] .
It's widely known that ligand binding to kinases is derived mainly by lipophilic vdW interactions [12, 13] . In most cases, kinase inhibitors binds to the ATP binding pocket of the kinase domain of the enzyme, and they form several H-bonds with the backbone and side chains of the amino acids present in this region (Hinge region) [14] . Previous studies have shown that for these kinds of receptors including ligand induced polarization by protein environment may be important and ligand binding is best described by QM/MM docking [15, 16] . Our previous results have also shown that the Lipophilic-vdW term may be the major factor that derives binding in this new series of inhibitors [10, 11] . Other studies have also indicated that the electrostatic effect may be important in certain cases [3] .
The ligand-protein binding process is too complex to be described by a single representation of the ligand-protein complex produced as a result of the rigid receptor docking [17] . The various levels of approximations necessary to make docking rapid make scientists sceptical to really believe its results [18] . Proteins are not static idles, they are a very complex, moving and viable machines [19, 20] . Introducing protein flexibility is increasingly important to describe the ligand-protein binding especially for targets known to be highly flexible such as kinases [21] [22] [23] . Kinases are known to be a very challenging target for molecular modelling, particularly conventional docking. In our previous studies, we have utilized different docking and scoring methods to include some receptor flexibility [10, 11] . These methods ranged from rigid docking with vdW radii scaling [17] , induced fit docking (IFD) [24, 25] and finally molecular dynamics (MD) simulations for some inhibitors against HER2 receptor [10, 11] .
In the current study, we are extending our insight understanding of the binding of the new series to their targets, EGFR and HER2 utilizing a much longer MD simulations.
These kinds of studies are important as certain conformational changes are not accessible at the conventional MD time scale. We are also planning to use our existing knowledge from these simulations in order to design new powerful inhibitors that can inhibit EGFR/HER2 more efficiently. Another motivation is to design members that are less liable to the problem of resistance to current chemotherapeutic agents. As references, we are comparing the new series with the both originally cocrystallized ligands, Lapatinib (EGFR) and SYR (HER2). Also, owing to the observed binding capability of the new series to interact with certain additional residues in the binding site, we are interested in analysing the interaction of the new series with some EGFR mutants, such as the famous T790M mutation [26, 27] . This mutation, among others, is responsible for the development of resistance against Lapatinib as well as other Tyrosine Kinase Inhibitor's (TKIs) [26, 27] . Previous studies have shown that acquired Lapatinib resistance due to the T790M (gate keeper) mutation is mostly driven by either severe steric clashes or disruption of the H-bonding network due to the surrounding water molecules [28] [29] [30] . Moreover, the T790M mutation was linked to increased affinity to ATP and only those inhibitors having a covalent binding mode can still be effective [31] .
In the two previous studies, we have identified the inhibitor M19 and M20 to be the most active against EGFR and HER2 [10, 11] . Herein, we are giving the results of a primary in silico screening of a designed compound library of 200 inhibitors. We will also represent one of the most promising members of the in silico screened compound library, which is the T9 inhibitor. Additionally, we will include SYR and Lapatinib as references for the simulation. We will also give some primary results for MD simulations of Lapatinib, M19 and T9 against the T790M EGFR mutant. In total, 9 complexes are subjected to long MD simulation; i. Lapatinib, M19 and T9 with wild type EGFR (WT), ii. Lapatinib, M19 and T9 with the T790M mutant EGFR(MUT) and iii. SYR, M19 and T9 with HER2 (WT). For simplicity, the wild type EGFR will be denoted as EGFR(WT) and the mutant strain will be denoted as EGFR(MUT).
Wild type HER2 will be denoted as HER2. In addition to MD simulations, we have carried out binding free energy calculations based either on a single snapshot (Prime-MM/GBSA) or ensemble of snapshots (AMBER-MM/PB(GB)SA). To account for the protein polarization effect, we have also rescored the relaxed MD complexes using QM/MM rescoring. Figure 1 represents the 2D structure of Lapatinib, a dually acting anti-EGFR/HER2 drug, SYR which is an HER2 inhibitor, in addition to the two leads that have been identified previously M19 and M20. We also include the 2D structure of the most active inhibitors of the new designed library identified in silico (T9). The in vitro measured IC 50 of M19 is (1.935 µM: EGFR and 1.035 µM: HER2). The new designed inhibitors will benefit from the main skeleton of M19 in addition to substitution at four different sites where we believe that substitution may give rise to more effective inhibitors. At this stage, we decided not to go to severe modifications on the main nucleus itself to keep essential binding motifs.
METHODS AND COMPUTATIONAL DETAILS

Design Rationale
As we have identified previously, the binding of the new series to either EGFR or HER2 is very similar, the N1 atom of the quinazoline ring binds to Met793 (EGFR) or Met801 (HER2). The bulky 4-anilinoquinazoline side group binds to the side pocket formed by displacement of the Cα-helix. The two terminal tails at positions R 1 and R 2 push the quinazoline ring for better filling of the hinge region and also form lipophilic interactions with the nearby residues [10, 11] .
Keeping in mind that the lipophilic vdW interaction terms is the most important term in these class of receptors, the primary focus on choosing different substituents is the halogen atoms at position R 3 and R 4 (-F, -Cl,-Br, -I, -CF3). For R 1 and R 2 positions, we increase the chain length from one carbon (-methoxy) to three carbons (-propoxy).
We also utilize the erlotinib and Lapatinib side chain tails instead of the pure alkoxy group substituents. The correctly docked inhibitors are given in supplementary data.
Note that this list contains also modifications for the second most active anti-EGFR ligand identified previously which is M20.
Docking and scoring calculations
For more details about the docking preparation and setup, please refer to our previous work [11] . All ligands are docked against the EGFR crystal structure (PDB code:
1xkk) using the same settings and ranked according to the XP_LipophilicEvdW term.
Only inhibitors that satisfy the presence of a two predetermined H-bonds constraints (with Met793 and the conserved water molecule) are kept. from the ligand. The dispersion corrected AM1 (AM1-D) [42, 43] Hamiltonian is utilized for the QM subsystem and for the MM subsystem, the ff03 force field is used [44] .
Molecular dynamic setup
Nine inhibitor-protein complexes (see above) obtained from the previous rigid (EGFR) and IFD (HER2) runs are subjected to extensive molecular dynamic simulations. For the Lapatinib-EGFR (PDB code: 1XKK) and the SYR-HER2 (PDB code: 3PP0) complexes, the original crystal structures are used [45, 46] . The structure preparation and the following MD simulations are performed using AMBER12 software package [41] applying the ff03 force field [44, 47] . Single point calculations of the corresponding inhibitors are performed at the B3LYP/cc-pVTZ level of theory in ether (ε ε ε ε=4.2) solvent applying the IEF-PCM model [48] using the Gaussian 09 program [49] . The inhibitor charges and other parameters are obtained using the RESP fitting [50] procedures and the general AMBER force field (GAFF) [51] . The complexes are then solvated with a box of TIP3P [52] water with a buffer size of 15Å and are neutralized by counter ions.
Each system is then subjected to four consecutive minimization steps. In each step, water molecules and ions are allowed to move freely for a 1000 steps of steepest descent minimization followed by 4000 steps of conjugate gradient minimization. . Each system is then subjected to a 10 ns "warming up" simulation, followed by 4 production simulations of 20 ns long each i.e., 80(4*20) ns in total applying the NVT ensemble at 300°K and using Berendsen temperature control [54] . In all simulation steps, long-range electrostatics are computed using the particle mesh Ewald (PME) [55] with a non-bonded cut-off of 12 Å. The edge effect is removed by applying periodic boundary conditions. All MD simulations are carried out using the PMEMD module of AMBER12 [41] . Binding energies are calculated from the MD trajectories using the PBSA module in AMBER12. formed as a result of large shift of the Cα-helix which also represents an inactive state of the protein [58] . This large shift creates a deep pocket in the back of the protein giving more room to accommodate bulky groups in the corresponding inhibitors.
RESULTS AND DISCUSSION
Almost
Other inhibitors can also bind the ATP pocket and nearby allosteric sites [58] . An example from the first class is Gefitinib (Iressa®) which is able to bind the active (DFG-in) state of the protein [60, 61] . This inhibitor, among others, is characterized by the presence of small side group at the 4-anilino site. An example of the second class is Lapatinib (Tykerb®) [62, 63] . In the contrary of Gefitinib, Lapatinib possess a bulkier group at the 4-anilino site. This bulky group is accommodated by a deep pocket created as a result of a large shift of the Cα-helix [45, 59] . The X-ray crystal structure of HER2 complexed with the inhibitors (SYR) has been released recently [64] . Previous modelling studies for HER2 have utilized homology modelling and using EGFR as a template owing to its high sequence similarity to HER2 (81%) [29, 30] .
In general, inhibitor binding to either EGFR or HER2 is driven by strong lipophilic vdW forces in addition to strong H-bond with a conserved Met residue at the hinge region with the N1 atom of the quinazoline ring. Other studies have also identified the importance of the conserved water molecule typically seen in many crystal structures of kinases co-crystalized with their corresponding ligands. However, it's an experimental fact that the binding energy contribution for this water molecule is essentially small and some of the active inhibitors previously reported lack the N atom at the 3 position (N3) that is responsible for the interaction with this water molecule [65, 66] . In certain cases, an extra cyano group at this site reduces the need of this N3 atom via direct interaction with the nearby Thr [67, 68] . For the new series under investigation, our primary results suggest that substitution of ring "C" by a halogen is essential to obtain such conserved water H-bond interaction, and this may be because of steric reasons. Table 1 reports the XP_Gscore and the XP_LipophilicEvdW docking scores of the 10 most active in silico designed inhibitors together with the substitution groups at R 1 , R 2 , R 3 and R 4 . Previously, we have shown that the lead structure M19 was identified to be the top active inhibitor against both EGFR and HER2 [10, 11] . For this section, we consider only EGFR as a result of data transferability which originates from high sequence similarity (81%). Our discussion is limited to the M19 modifications as M19 is the dually acting inhibitor whereas M20 shows a very weak anti-HER2 inhibitory effect (IC 50 against EGFR: 2.582 µM and against HER2 99.96 µM) [10, 11] . Given the exceptional power of the XP_LipophilicEvdW score to qualitatively identify the top active anti-EGFR as we have shown previously, we will mainly consider that score in the present docking study. The derivatives also appear in the table according to this score.
Docking and scoring
As we can see in Table 1 We didn't attempt to test electron withdrawing groups (EWG) at these two sites as previous studies have shown that EWG at these two sites of the anilinoquinazoline scaffold tend to decrease the anti-tumour activity significantly [69, 70] . Also, it seems that optimal activity is achieved with Chlorination at R 3 and R 4 positions as the case in T9 (XP_LipophilicEvdW score of -9.40). Again, synthesis and biological investigation for this new series is warranted to build such solid conclusions. is not essential for the anti-EGFR and/or anti-HER2 activity, recent studies link some binding problems against kinases to the disruption of such favouring interaction [12, 30] . Another two potential sites for the presence of water molecules are the S2 site in which water molecule bind to the aniline hydrogen, the third site S3 is linked to the nearby Gln amino acid. Figure 3 shows the potential locations of these three sites around the inhibitors under study.
Molecular dynamic simulations
General binding remarks
Water molecules occupancies
Subsequent analysis of the MD trajectories shows that the H-bonds occupancies of these three sites are different for different inhibitors-protein complexes. Table 2 represents the % occupancy of the potential water mediated H-bonds as a function of the simulation time. In all cases, an upper distance cut-off of 3.5 Å and a lower angle cut-off of 120° are used. Figure 3 displays potential water occupancy sites (S1, S2
and S3) among the studied inhibitors. As there's a possibility for the two hydrogens of the same water molecule or more than one water molecule to interact simultaneously, one may expect that the occupancy may be even more than 100%.
In all situations, the most conserved occupancy is observed with the S3 site. The T9-HER2 complex achieves the highest value of 123.54% of the simulation time for this site (S3). We should stress here that neither of these water molecules have been got from the original crystal structure nor constrained to their 3D coordinates. However, as the occupant water molecules at this site (S3) don't directly interact with the inhibitor, this site may have the least influence among the three observed water sites. The most interesting water %occupancy is observed with the S1 site. The highest occupancies are achieved with either SYR-HER2(WT) with a %occupancy of 97.54
followed by Lapa-EGFR(WT) with a value of 94.50. For the new inhibitors, both the lead (M19) and the optimized structure (T9) show an interesting behaviour. M19
seems to completely lack such interaction in all situations with a maximum value of 1.71% for its complex with EGFR(WT). Such low occupancy value can be considered essentially insignificant. In contrast to M19, T9 seems to have a much higher occupancy at the S1 site of about 91.05% with HER2(WT) and a value of 70.03% with EGFR(WT). As expected and as a result of the increased hydrophobicity around the S1 site due to the T790M mutation, water occupancy at this site is significantly reduced from 94.50% in Lapa-EGFR(WT) to 28.69% in Lapa-
EGFR(MUT) and from 70.03% in T9-EGFR(WT) to Zero% in T9-EGFR(MUT). A
quick look on the literature show that "almost" all effective anilinoquinazoilne EGFR and/or HER2 competitive inhibitors, particularly the currently marketed inhibitors, are substituted at ring "C" mostly with an electron withdrawing groups, such as halogen and/or ethyne groups [66, 69, 73] . In the new series, the lead structure M19 doesn't have but the modified one T9 does have such substitution, so, T9 possess such water mediated interaction at S1 as we showed before. Our primary investigation showed that this may be because of steric reasons. Because of the existence of different rotomeric conformations of the side chains of nearby residues responsible for binding to this bridging water molecule at the S1 site, i.e. Thr790 and Thr854, such interaction is possible in Lapatinib and T9 but not possible in M19. The same is true for inhibitors-HER2 complexes and the differences between rotomeric structures of Thr798 and Thr862 are responsible for the existence of high water occupancy at the S1 site for SYR (97.54%) and T9 (91.05%) but as low as 0.11% for M19.
Binding to the conventional hinge residues
As mentioned before, inhibitor binding to both EGFR and HER2 is driven mainly by shown that for EGFR receptors, acquired resistance due to the T790M mutation prevents stable interaction with competitive inhibitors, including Lapatinib. This has been previously proposed to be attributed to several reasons; (i) steric clashes, (ii) increased sensitivity to ATP and (iii) disruption of the surrounding waters mediated H-bonds [29, 30] . Indeed, we show that the surrounding water mediated H-bonds network is severely disrupted in case of the T790M mutation. However, we believe that such disruption is not enough alone to explain the huge reduction in the ability of Lapatinib to inhibit EGFR as a consequence of this mutation. The anti-tumour activity of Lapatinib against EGFR is severely decreased going from the EGFR(WT)
with an IC 50 of 0.022 µM to EGFR(MUT) with an IC 50 of 3.3 µM [29] . We believe that a combination of the aforementioned explanations is the most likely reason. [74] . This has been previously discussed for the EGFR T790M mutant binding to Gefitinib [74] . In all other complexes, the average value of this H-bond ranges between 2-2.5 Å.
Binding to the additional hinge residues
Previously we have demonstrated the ability of the new inhibitors to bind to additional hinge residues in both EGFR and HER2 binding sites, and due to the high sequence similarity between both receptors, the locations of such interactions are similar [10, 11] . In general, the most important interactions are the two charge assisted H-bonds formed with Asp855 and Lys745 (EGFR) or Asp863 and Lys753 (HER2) and mediated by the N-H group of ring "D" and the extra imino group on the same ring, respectively. Because of structural reasons, neither SYR nor Lapatinib are able to form such charge assisted interactions. However, another possibility for SYR interaction with Asp863 is via the terminal hydroxy group at the other side of the molecule. This interaction is indeed observed in the crystal structure itself and is formed during the simulation. Figure 5 displays the interaction of T9 and M19 with the three receptor types (EGFR(WT), EGFR(MUT) and HER2). As such static representation may be misleading as it doesn't provide any dynamic information, This demonstrated ability of the new inhibitors to bind to these extra residues is a good point that may favour their future development. It's known that some of the very challenging mutations that result in resistance to current EGFR/HER2 are those present in the vicinity of the hinge region. An example of such mutations is the stubborn T790M mutation which is known to be present in more than 50% of all patients whose tumours showed an acquired resistance for TKIs [75, 76] . Formation of very strong interactions with additional residues may retain the antitumor activity even in the EGFR/HER2 resistant strains including the T790M mutation. Although it has been shown that irreversible inhibitors may be the agents of choice for the resistant strains, toxicity concerns may be a problem for these agents [28, 77, 78] . ). This is consistent with experimentally measured IC 50 for M19 against HER2 (1.035 µM) and EGFR (1.935 µM) [10, 11] . Also, we tried to include all surrounding residues within the binding site in the QM region as no much QM accuracy is expected to be gained considering only the ligand as the QM subsystem. Other binding energy scores show discrepancies as a result of different modelling techniques and theory levels. Table 5 reports the individual binding energy components calculated using the AMBER/MM-PBSA tool. The total binding energy mentioned in that table (∆E tot ) doesn't include the desolvation penalties included in Table 4 , i.e., we can consider that ∆E tot is a "gas phase" binding energy. ).
Binding energy calculations
Total binding energy
Component contribution to total binding energy
Per-residue binding energy decomposition
Individual binding energy components on per-residue decomposition analysis are also shown in Figure 6 . We choose only the most important residues to show. Choice is ). Discrepancies between T9 and M19 for the ∆E col term regarding these two amino acid residues seem to be non-specific in nature as they are not directly correlated with the H-bond occupancies ( [58] . Lapatinib forms an "almost" irreversible complex with EGFR with a t 1/2 of about 224 minutes [29] . Further development, synthesis and biological testing are warranted in order to achieve the best outcome.
CONCLUSIONS
In this study, we have characterized the binding modes and exact mechanisms of inhibition of a recently synthesized 4-anilinoquinazoline series against both wild type and T790 mutant EGFR in addition to wild type HER2. It seems that substitution at ring "C" is essential to achieve optimum interaction with the conserved water Table 4 : Experimental %inhibition together with simulated binding energies and scores for the MD produced complexes (kcal·mol -1 ).
a Calculations are carried out using the QM/MM-PBSA script from Schrödinger and ignoring solvation, the B3LYP/LACVP* //OPLS2005 level of theory is applied, QM substructure composed of inhibitor atoms only. b QM system composed of ligand and the nearby residues within 5 Å, QM system was treated at the dispersion corrected AM1 Hamiltonian (AM1-D) and MM system was treated at the AMBER-ff03 force field. 
